Pfizer Inc. (PFE)
Pfizer: Irrational Anti-Vaccine Fear
Pfizer's stock has become appealing due to irrational vaccine fears. Market fears about RFK Jr.'s potential anti-vaccine stance are likely overblown, as neither he nor Trump have indicated plans to block vaccines. Pfizer's strong growth in oncology and specialty care, along with cost-cutting measures, suggest the stock is undervalued at below 10x EPS guidance.
Is Pfizer a Millionaire Maker?
With a market capitalization of more than $143 billion today, Pfizer (PFE 0.83%) stock won't make anyone into a millionaire unless they're willing to commit a large amount of capital and then hold the stock for a very long period of time, reinvesting all the dividends they receive along the way. Big pharma businesses simply don't grow quickly enough to deliver investors the massive returns that are necessary to generate millions from a humble starting sum.
Reader Mailbag: Is Pfizer (PFE) a Good Deal Right Now?
November was an interesting month for pharmaceutical companies in general. President-elect Trump officially announced that Robert F.
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Pfizer (PFE) closed at $25.23, marking a -1.33% move from the previous day.
Pfizer: Peer-Leading Dividend And Potential Substantial Shareholder Returns
Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with significant Seagen acquisition integration ongoing. Q3 2024 results show 32% YoY revenue increase, driven by COVID-19 products and 14% growth excluding one-time impacts, with improved margins. Oncology revenue up 31% YoY, promising pipeline advancements, and strong vaccine portfolio, including potential Lyme disease vaccine and promising Cachexia treatment.
Pfizer Stock: A Golden Buying Opportunity (Rating Upgrade)
I upgrade Pfizer to "Strong Buy" due to its undervaluation, strong pipeline, and operational growth despite recent stock price declines. Pfizer's Q3 FY2024 earnings showed significant revenue and EPS growth, driven by COVID-19 therapies and oncology products, indicating robust strategic execution. The company's diversified portfolio, including successful vaccines and promising new drugs, positions it for long-term success and potential stock price re-rating.
PFE or NVO: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer: Too Cheap To Ignore
Pfizer's fundamentals are improving, with solid Q3 earnings, upgraded 2024 guidance, and a strategic pivot towards the fast-growing oncology market. The stock is undervalued with a 32% upside potential based on a $33.39 intrinsic value per share, using the dividend discount model. Despite recent share price weakness, Pfizer offers a compelling forward dividend yield, supported by strong revenue growth and aggressive R&D spending.
Pfizer Stock Falls 8% in a Month: Should You Buy the Dip?
Investors with a long-term horizon may consider buying PFE stock at its present attractive valuation.
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Things aren't getting much better for Pfizer (PFE -1.29%). The company is still suffering from the significant drop in sales of its coronavirus products and the less-than-impressive financial results it has produced during the past two years.
What's Happening With PFE Stock?
Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent anti-vaccine activist.
